(ATN) CD4 Treatment Test Near?

DonateNow
Print this article

(ATN) CD4 Treatment Test Near?

AIDS TREATMENT NEWS No. 062 - August 12, 1988
John S. James


An article in the August 9 San Francisco Chronicle first reported that Genentech, a biotechnology company in South San Francisco, had been granted permission for human tests of CD4, its genetically engineered AIDS treatment. The company applied for permission in January.

In the week before the article, two people who were consid- ering volunteering had asked us what we knew about the treatment.

CD4 is the protein found in the CD4 receptor site on T-helper and certain other cells. In the laboratory, manufactured CD4 provides an alternate target for HIV, preventing it from infecting new cells.

There will be a risk for the first person or first few per- sons who try this treatment, however. Some experts fear that injecting CD4 could cause the body to develop antibodies against its own T-helper cells, making AIDS symptoms worse. Animal and laboratory tests have been successful, but because this drug is so specific for the human immune system, these tests cannot rule out the possible danger.

Despite the risk, CD4 represents an important potential treatment for many people. It should be tested quickly. San Francisco General Hospital and other medical centers are now preparing to run initial trials.


880812
ATN06203


Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .